(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 March 2012 (08.03.2012)

PCT

(10) International Publication Number
WO 2012/031198 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2011/050322

(22) International Filing Date:
2 September 2011 (02.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/379,840 3 September 2010 (03.09.2010) US
61/440,460 8 February 2011 (08.02.2011) US

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CLARKE, Neil, James** [GB/GB]; Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **JOHANSON, Kyung, Oh** [US/US]; 25 Haymarket Lane, Byrn Mawr, PA 19010 (US). **JONAK, Zdenka, Ludmila** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **TAYLOR, Alexander, H.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **HOPSON, Christopher, B.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **TRULLI, Stephen, H.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **HASKOVA, Zdenka** [CZ/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **LEE, Judithann, M.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **WHITE, John, R.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **XUE, Yu** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: **LONG, William, P.** et al.; GlaxoSmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NOVEL ANTIGEN BINDING PROTEINS

(57) Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

WO 2012/031198 A2